A phase I/II study of sunitinib malate (SU011248) in the treatment of patients with malignant gastrointestinal stromal tumor (GIST) previously treated by imatinib mesylate

Trial Profile

A phase I/II study of sunitinib malate (SU011248) in the treatment of patients with malignant gastrointestinal stromal tumor (GIST) previously treated by imatinib mesylate

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Nov 2009

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Nov 2009 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov
    • 17 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top